Trial Profile
A Study on the Adverse Effect Profile of the 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Normal Tension Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2016
Price :
$35
*
At a glance
- Drugs Tafluprost (Primary)
- Indications Angle-closure glaucoma; Low tension glaucoma; Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Santen Pharmaceutical
- 12 Jun 2014 New trial record